John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.
John Leonard, MD
Advertisement
Articles by John Leonard, MD
John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.
John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.
Advertisement
Latest Updated Articles
Dr. Leonard on the Potential for Combinations With PI3K Inhibitors in Follicular LymphomaPublished: July 6th 2021 | Updated:
- Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma
Published: July 7th 2021 | Updated:
Dr. John Leonard on Treatment Options for Relapsed Follicular LymphomaPublished: March 20th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5